Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
express system | HEK293 |
product tag | C-His-Avi |
purity | > 95% as determined by Tris-Bis PAGE |
background | Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
molecular weight | The protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Tris-Bis PAGE result. |
available size | 100 µg, 500 µg |
endotoxin | Less than 1EU per μg by the LAL method. |
Biotinylated Human VEGF165 Protein 4585
$525.00 – $1,750.00
Summary
- Expression: HEK293
- Functional: Yes (ELISA)
- Amino Acid Range: Ala27-Arg191
Biotinylated Human VEGF165 Protein 4585
protein |
---|
Size and concentration 100, 500µg and lyophilized |
Form Lyophilized |
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Storage buffer Shipped at ambient temperature. |
Purity > 95% as determined by Tris-Bis PAGE |
target relevance |
---|
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
Protein names Vascular endothelial growth factor A, long form (L-VEGF) (Vascular permeability factor) (VPF) [Cleaved into: N-VEGF; VEGFA] |
Gene names VEGFA,VEGFA VEGF |
Protein family PDGF/VEGF growth factor family |
Mass 9606Da |
Function [N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).; [VEGFA]: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed:34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).; [Isoform VEGF165B]: Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
Subellular location [N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions.; [VEGFA]: Secreted .; [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix .; [Isoform VEGF121]: Secreted .; [Isoform VEGF165]: Secreted .; [Isoform VEGF189]: Secreted. Note=Cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. |
Tissues Higher expression in pituitary tumors than the pituitary gland.; [Isoform VEGF189]: Widely expressed.; [Isoform VEGF165]: Widely expressed.; [Isoform VEGF121]: Widely expressed.; [Isoform VEGF206]: Not widely expressed.; [Isoform VEGF145]: Not widely expressed. |
Structure [VEGFA]: Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042). Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889). |
Post-translational modification [Vascular endothelial growth factor A, long form]: Produced by use of an alternative upstream CUG codon and post-translationally processed into the N-terminal N-VEGF form and the C-terminal secreted VEGFA form. |
Target Relevance information above includes information from UniProt accession: P15692 |
The UniProt Consortium |
Data
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.pmid | title | authors | citation |
---|
Protocols
relevant to this product |
---|
Documents
# | ||
---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.